These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10665462)

  • 1. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.
    Arango C; Kirkpatrick B; Buchanan RW
    J Nerv Ment Dis; 2000 Jan; 188(1):50-3. PubMed ID: 10665462
    [No Abstract]   [Full Text] [Related]  

  • 2. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
    Poyurovsky M; Pashinian A; Gil-Ad I; Maayan R; Schneidman M; Fuchs C; Weizman A
    Am J Psychiatry; 2002 Jun; 159(6):1058-60. PubMed ID: 12042201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.
    Spina E; De Domenico P; Ruello C; Longobardo N; Gitto C; Ancione M; Di Rosa AE; Caputi AP
    Int Clin Psychopharmacol; 1994; 9(4):281-5. PubMed ID: 7868850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center.
    Silver H; Bilker WB
    J Clin Psychopharmacol; 2013 Oct; 33(5):710-1. PubMed ID: 23899641
    [No Abstract]   [Full Text] [Related]  

  • 5. Negative symptoms of schizophrenia are improved by paroxetine added to neuroleptics: a pilot study.
    Jockers-Scherübl M; Godemann F; Pietzcker A
    J Clin Psychiatry; 2001 Jul; 62(7):573. PubMed ID: 11488373
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.
    Buchanan RW; Kirkpatrick B; Bryant N; Ball P; Breier A
    Am J Psychiatry; 1996 Dec; 153(12):1625-7. PubMed ID: 8942462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
    Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
    J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.
    Keck PE; Corya SA; Altshuler LL; Ketter TA; McElroy SL; Case M; Briggs SD; Tohen M
    J Clin Psychiatry; 2005 May; 66(5):611-6. PubMed ID: 15889948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
    Shelton RC; Williamson DJ; Corya SA; Sanger TM; Van Campen LE; Case M; Briggs SD; Tollefson GD
    J Clin Psychiatry; 2005 Oct; 66(10):1289-97. PubMed ID: 16259543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.
    Ostroff RB; Nelson JC
    J Clin Psychiatry; 1999 Apr; 60(4):256-9. PubMed ID: 10221288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
    Phillips KA
    Am J Psychiatry; 2005 Feb; 162(2):377-9. PubMed ID: 15677604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone for exclusively negative symptoms.
    Lane HY; Liu CC; Chang WH
    Am J Psychiatry; 1999 Feb; 156(2):335. PubMed ID: 9989576
    [No Abstract]   [Full Text] [Related]  

  • 14. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind trial of adjunctive allopurinol for schizophrenia.
    Dickerson FB; Stallings CR; Origoni AE; Sullens A; Khushalani S; Sandson N; Yolken RH
    Schizophr Res; 2009 Apr; 109(1-3):66-9. PubMed ID: 19195842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.
    Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO
    Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.
    Stein MB; Kline NA; Matloff JL
    Am J Psychiatry; 2002 Oct; 159(10):1777-9. PubMed ID: 12359687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine augmentation of fluoxetine in body dysmorphic disorder.
    Phillips KA
    Am J Psychiatry; 2005 May; 162(5):1022-3. PubMed ID: 15863817
    [No Abstract]   [Full Text] [Related]  

  • 19. Obsessive-compulsive symptoms with risperidone.
    Mahendran R
    J Clin Psychiatry; 1999 Apr; 60(4):261-3. PubMed ID: 10221290
    [No Abstract]   [Full Text] [Related]  

  • 20. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
    Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC
    Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.